Skip to search formSkip to main contentSkip to account menu

Gynecologic Oncology Group

Known as: GOG 
A non-profit NCI-supported organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific… 
National Institutes of Health

Related topics

Related topics

1 relation
GOG

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA…
5500 Background: Paclitaxel (PC) is a standard initial therapy for advanced endometrial cancer (EC). We evaluated efficacy and… 
2009
2009
A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group (GOG) Study.
5531 Background: Bevacizumab (BV) is a recombinant, humanized monoclonal antibody directed against vascular endothelial growth… 
2008
2008
Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
PURPOSE To determine the cost effectiveness of intraperitoneal versus intravenous regimens for adjuvant treatment of optimally… 
2004
2004
Analysis of CHEK2 gene for ovarian cancer susceptibility.
Review
2004
Review
2004
Update on Gynecologic Oncology Group (GOG) Trials in Ovarian Cancer
The Gynecologic Oncology Group (GOG) has conducted a series of randomized trials in advanced ovarian cancer patients, both with… 
Review
2002
Review
2002
Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182).
Despite improvements in median and overall survival using a combination of platinum and paclitaxel, long-term survival rates for… 
Review
1999
Review
1999
The use of adjuvant radiation therapy by members of the Society of Gynecologic Oncologists.
UNLABELLED OBJECTIVES. The aim of this study was to determine the attitudes of the members of the Society of Gynecologic… 
Highly Cited
1998
Highly Cited
1998
A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study.
OBJECTIVE To determine the response rate and associated toxicity of weekly CPT-11 in squamous carcinoma of the cervix. METHODS… 
1996
1996
A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium.
In other Gynecologic Oncology Group (GOG) studies, ifosfamide demonstrated antineoplastic activity against ovarian epithelial… 
Highly Cited
1989
Highly Cited
1989
Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study.
Ifosfamide (isophosphamide) and mesna (2-mercaptoethane sodium sulfonate) were administered intravenously at monthly intervals to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)